Group 1 - The core viewpoint of the article highlights the performance of the China Securities Hong Kong 300 Mainland High Beta Index, which has shown significant increases over various time frames, including a 14.17% rise in the past month, a 22.33% rise in the past three months, and a 33.19% rise year-to-date [1] - The index is designed to reflect the overall performance of securities listed on the Hong Kong Stock Exchange from multiple strategic investment perspectives, with a base date of December 30, 2005, set at 1000.0 points [1] - The top ten weighted stocks in the index include InnoCare Pharma (4.02%), Sunac China (3.78%), China Merchants Securities (2.93%), Dongfang Zhenxuan (2.79%), China Cinda Asset Management (2.69%), China Jinmao (2.6%), MicroPort Scientific (2.48%), CICC (2.42%), GF Securities (2.39%), and China Galaxy Securities (2.39%) [1] Group 2 - The index's holdings are entirely composed of stocks listed on the Hong Kong Stock Exchange, with a sector breakdown showing that finance accounts for 26.87%, information technology for 19.21%, healthcare for 17.51%, real estate for 16.45%, consumer discretionary for 10.51%, communication services for 6.08%, and industrials for 3.38% [1] - The index sample is adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample stock is delisted or undergoes corporate actions like mergers or suspensions [2]
中证香港300内地高贝塔指数报1121.21点，前十大权重包含中国金茂等